Skip to content

Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve

A Whole-genome Sequencing Base Study on Genetic Pathogenesis of Diminished Ovarian Reserve

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04711772
Enrollment
140
Registered
2021-01-15
Start date
2020-09-01
Completion date
2022-12-31
Last updated
2021-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diminished Ovarian Reserve

Keywords

Diminished Ovarian Reserve, Whole-genome Sequencing

Brief summary

The study aims to explore the genetic pathogenesis of diminished ovarian reserve via whole-genome sequencing technology in Chinese women.

Detailed description

Diminished ovarian reserve (DOR), a pathological condition of reduced quantity and quality of oocytes, has severe impairment on women fertility. Some women experience DOR may develop into premature ovarian insufficiency (POI), which defined as a cessation of function of ovaries in women younger than 40 years old. The pathogenesis of DOR is multiple and the etiology of most DOR remains obscure. Genetic factors, including chromosome abnormality, genetic variation, and non-coding RNA abnormal regulation are considered the major mechanisms of DOR. More than 12 gene mutations, detected by whole-exome sequencing (WES), have been implicated as potential causes of DOR. However, we have found that coding gene mutation detected by WES may only account for a small part of DOR. Whole-genome sequencing (WGS) has been developing into an important strategy for identifying exons, introns and mitochondrial DNA mutation. However, the application of WGS is still lacking in detecting pathogenic genes of DOR. Therefore, this study intends to explore the possible pathogenic genes by WGS in order to deeply and comprehensively understand the pathogenic mechanism of DOR.

Interventions

Whole-genome sequencing will be preformed for each participate to explore the potential disease-causing genes of DOR.

Sponsors

Ferring Pharmaceuticals
CollaboratorINDUSTRY
Nanfang Hospital, Southern Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

DOR group: 1. age between 18 and 40 years; 2. number of oocytes obtained in previous ovarian stimulation cycles ≤3; 3. bilateral ovarian antral follicle count (AFC) \< 5-7; 4. serum anti-Mullerian hormone (AMH) \<0.5-1.1ng/ml. Control group: 1. age between 18 and 40 years; 2. bilateral AFC ≥8; 3. serum AMH ≥1.2ng/ml; 4. regular menstrual cycles occurring every 25-35 days.

Exclusion criteria

The

Design outcomes

Primary

MeasureTime frameDescription
Genotype1/9/2020-31/12/2022Measure the genotype by whole-genome sequencing in all participates.

Countries

China

Contacts

Primary ContactShi-ling Chen, M.D, Ph.D
chensl_92@163.com+86-020-62787604

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026